We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+6.8%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$9.57B
AUM Growth
+$1.06B
Cap. Flow
+$745M
Cap. Flow %
7.79%
Top 10 Hldgs %
36.3%
Holding
159
New
27
Increased
34
Reduced
20
Closed
32

Top Buys

Rank Stock Value
1
AGN
Allergan plc
AGN
+$202M
2
COO icon
Cooper Companies
COO
+$180M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$78.3M
4
SHPG
Shire pic
SHPG
+$77.9M
5
WMGI
Wright Medical Group Inc
WMGI
+$75.3M

Top Sells

Rank Stock Value
1
ITMN
INTERMUNE INC
ITMN
+$240M
2
VTRS icon
Viatris
VTRS
+$184M
3
AGN
Allergan Inc
AGN
+$107M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$89.3M
5
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$43.7M

Sector Composition

Rank Sector Weight
1 Healthcare 83.95%
2 Financials 0.07%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GEVA
101
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
$7.64M 0.08%
111,100
– –
ABT icon
102
Abbott
ABT
$190B
$7.49M 0.08%
180,000
– –
LLY icon
103
Eli Lilly
LLY
$1.09T
$7.26M 0.08%
112,000
-288,000
-72% -$18.2M
NSPR icon
104
InspireMD
NSPR
$30.9M
– –
-1
Closed -$15.5M
AET
105
DELISTED
Aetna Inc
AET
$6.48M 0.07%
80,000
– –
ARQL
106
DELISTED
Arqule Inc
ARQL
$6.39M 0.07%
5,702,000
– –
IPXL
107
CALL
DELISTED
Impax Laboratories, Inc.
IPXL
$5.93M 0.06%
+250,000
New +$6.4M
MDXG icon
108
MiMedx Group
MDXG
$646M
$5.67M 0.06%
795,400
– –
AMAG
109
DELISTED
AMAG Pharmaceuticals
AMAG
$5.04M 0.05%
+158,000
New +$3.37M
SUPN icon
110
Supernus Pharmaceuticals
SUPN
$2.77B
$5.04M 0.05%
580,000
– –
DVA icon
111
DaVita
DVA
$15.6B
$4.75M 0.05%
65,000
– –
CSII
112
DELISTED
Cardiovascular Systems, Inc.
CSII
$4.02M 0.04%
170,000
-36,000
-17% -$1.02M
FATE icon
113
Fate Therapeutics
FATE
$267M
$3.53M 0.04%
692,900
– –
UPI
114
DELISTED
UROPLASTY INC-NEW
UPI
$3.41M 0.04%
1,363,500
– –
BSX icon
115
Boston Scientific
BSX
$68.5B
$3.21M 0.03%
271,700
– –
CRIS icon
116
Curis
CRIS
$9.59M
$2.75M 0.03%
975
– –
VIRX
117
CALL
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$2.5M 0.03%
+1,667
New +$2.41M
DSCI
118
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$2.5M 0.03%
300,000
– –
LUMO
119
CALL
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$2.14M 0.02%
11,111
– –
XTNT icon
120
Xtant Medical Holdings
XTNT
$57.7M
$2.13M 0.02%
39,620
– –
BLRX
121
BioLineRX
BLRX
$12.3M
$1.75M 0.02%
1,892
– –
ACHN
122
DELISTED
Achillion Pharmaceuticals
ACHN
$1.58M 0.02%
+158,000
New +$1.47M
AMRN
123
Amarin Corp
AMRN
$298M
$436K ﹤0.01%
20,000
– –
ALBO
124
DELISTED
Albireo Pharma Inc
ALBO
$350K ﹤0.01%
6,990
– –
ALKS icon
125
Alkermes
ALKS
$8.31B
– –
-433,300
Closed -$21.8M
3 4
5
6 7

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q3 2014 Portfolio in Review

As of Q3 2014, OrbiMed held 159 positions worth $9.57B, up 12% from $8.52B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

OrbiMed deployed $745M of net new capital in Q3 2014, opening 27 new positions and adding to 34 existing holdings. Its largest new stake was Cooper Companies: 4,570,800 shares worth $178M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 83% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Viatris, an estimated $184M trimmed.

  • OrbiMed's largest Q3 2014 buy was Cooper Companies: 4,570,800 shares worth $178M.
  • OrbiMed added most to Allergan plc in Q3 2014, an estimated $202M increase.
  • OrbiMed's biggest Q3 2014 reduction was Viatris, cutting an estimated $184M.
  • OrbiMed fully exited INTERMUNE INC in Q3 2014, selling an estimated $240M.
  • OrbiMed's ten largest holdings make up 36% of its $9.57B portfolio in Q3 2014.
  • OrbiMed opened 27 new positions and closed 32 in Q3 2014.
  • OrbiMed's portfolio value rose 12% quarter-over-quarter to $9.57B.

Based on OrbiMed's 13F filing for Q3 2014, filed 14 Nov 2014.